<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233830</url>
  </required_header>
  <id_info>
    <org_study_id>D2600C00004</org_study_id>
    <nct_id>NCT01233830</nct_id>
  </id_info>
  <brief_title>Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Japanese Volunteers</brief_title>
  <official_title>A Phase I, Single Centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 Solution After Administration of Multiple Ascending Doses for 12 Days in Young and Elderly Healthy Japanese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety, tolerability and pharmacokinetics of AZD2423
      in young and elderly healthy Japanese volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse events</measure>
    <time_frame>Ranging from screening visit (Visit Day 1) to follow-up visit (Visit Day 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Ranging from screening visit (Visit Day 1) to follow-up visit (Visit Day 3)</time_frame>
    <description>Changes from baseline in systolic blood pressure, pulse rate and body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms</measure>
    <time_frame>Ranging from screening visit (Visit Day 1) to follow-up visit (Visit Day 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Variables (hematology, urinalysis and clinical chemistry)</measure>
    <time_frame>Ranging from screening visit (Visit Day 1) to follow-up visit (Visit Day 3)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration over time</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60 and 72 hours after the first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2423</intervention_name>
    <description>oral solution</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral solution</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

          -  Healthy Japanese male volunteers aged ≥20 to ≤45 years and healthy Japanese male and
             female volunteers aged ≥65 to ≤80 years with suitable veins for cannulation or
             repeated venipuncture

          -  Have a body mass index (BMI) between ≥17 and ≤27 kg/m2, as calculated by the
             investigator(s), and weigh at least 45 kg and no more than 100 kg

          -  Clinically normal physical findings including supine blood pressure, pulse rate, ECG,
             and laboratory assessments in relation to age, as judged by the investigator(s)

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder which, in the opinion of the
             investigator(s), may either put the volunteer at risk because of participation in the
             study, or influence the results or the volunteer's ability to participate in the study

          -  History or presence of gastrointestinal, hepatic or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism or excretion of
             drugs

          -  Any clinically significant illness/infection or medical/surgical procedure or trauma,
             as judged by the investigator(s), within 3 months of the first administration of
             investigational product or known malignancy within the past 5 years (with the
             exception of successfully treated basal cell carcinoma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bror Jonzon, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Södertälje</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akimasa Watanabe</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyushu Clinical Pharmacology Research Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>April 11, 2011</last_update_submitted>
  <last_update_submitted_qc>April 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>safety, tolerability, pharmacokinetics, AZD2423, Japanese</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

